I should delete the post right before this one on
Post# of 72440
The company did NOT defer pursuing the ABSSSI trial because it was greedy.
It deferred it because the trial was going to cost tens of millions of dollars that the company did not have, whereas a few million could get the Bril-OM formulation to Phase 3.
This has been shown to be the correct strategy.
So anyone who believes Sqott's claims not to be a basher need only read his lie-filled post.